NRXS Company Profile and Key Details

NeurAxis, Inc. generated EPS of -$1.02 over the past year. Five-year average earnings growth is -14.82%. Wall Street analysts project EPS growth of 51.14% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $13.00 to $8.00. The high target offers 118.49% upside. The low target suggests 34.45% downside. The mean target is $10.50. This offers 76.47% upside. NeurAxis, Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by -40.62%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 29.17% in May 12, 2025.

Short-term trend indicators are bearishly aligned (SMA20 18.16%, SMA50 27.45%, SMA200 82.46%). The stock’s 14-day RSI is 65.34 (firm momentum), while the ATR of 0.42 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -8.23% below its high and over 327.82% above its low. Average 10-day trading volume of 60.73 thousand shares is below the 3-month average of 87.95 thousand, indicating normal recent market interest.

NeurAxis, Inc. (AMEX:NRXS) closed at $5.95 USD, gaining $0.14 (2.41%) from the previous close of $5.81. The stock is currently mid-range between its 52-week high and low $2.21 and $9.33. With a market capitalization of about $74.24 million, NeurAxis, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.48). Key stats such as the average daily volume over the past year has been around 86.84 thousand shares, in line with its 52-week average. Headquartered in Carmel, IN, NeurAxis, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Brian Carrico, the company employs approximately 24 people and listed since August 09, 2023. NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices.

NeurAxis, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.60. This means the shares are trading below this model’s fair value.

NeurAxis, Inc. has 12.56 million shares outstanding. The public float is 8.45 million shares, elevated short interest at 4.29% of float. This equals 418.13 thousand shares. The short ratio is 5.22 days. Institutional investors hold 28.08% of the float. Insiders own 19.82%. Carrico Brian Allen holds 348.18 thousand shares, Carrico Thomas Joeseph has 331.90 thousand shares and Aharon Gil has 286.14 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

NeurAxis, Inc. trades at a P/E ratio of -7.75, slightly below the S&P 500 average, with a price-to-sales ratio of 14.01 and a price-to-book ratio of 10.74 reflecting a rich premium to book value. The P/FCF stands at -13.22, also below market averages. Compared to sector medians, NeurAxis, Inc. P/S is trading rich, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that NeurAxis, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.73%, with price expected at $5.49 by September 16, 2026, within a range of $5.19 to $5.78 3-Month Outlook: Projected fall of -78.82%, reaching $1.26 by December 01, 2026, with a range of $0.97 to $1.50. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 02, 2027, within a range of $0.00 to $1.45.

NeurAxis, Inc. (AMEX:NRXS) shares are flat 2.42% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows NeurAxis, Inc. trading at a premium to the broader market with a P/E of -7.75. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.33, suggesting 56.81% upside. Our AI forecast model points to short-term weakness (-7.73% over two weeks), a medium-term fall (-78.82% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.